Welcome to our dedicated page for CERO THERAPEUTICS HOLDINGS SEC filings (Ticker: CEROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CERO THERAPEUTICS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CERO THERAPEUTICS HOLDINGS's regulatory disclosures and financial reporting.
CERO Therapeutics Holdings, Inc. filed a Form 8-K reporting that it furnished an Investor Presentation dated September 2025 as Exhibit 99.1. The company explicitly states that information on its website is not incorporated or made part of the filing. The submission was signed by Chris Ehrlich, Chief Executive Officer. No financial results, transactions, or forward-looking guidance are included in the disclosed text; the filing functions to furnish corporate presentation materials to the SEC record rather than to amend prior disclosures.